ReShape Lifesciences® Announces Strategic Cost Reductions and Provides Update on the Merger Agreement with Vyome Therapeutics and Asset Purchase Agreement with Biorad Medisys

Stock Information for Singular Genomics Systems Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Singular Genomics Systems Inc.

ReShape Lifesciences® Announces Partial Adjournment of Special Meeting of Stockholders
ReShape Lifesciences® to Host Inaugural Lap-Band® Surgeon Summit
ReShape Lifesciences® to Host Special Meeting of Stockholders on July 24, 2025
ReShape Lifesciences® Granted U.S. Patent Related to an Intragastric Balloon System
ReShape Lifesciences® Regains Compliance with Nasdaq Minimum Stockholders Equity Requirement
ReShape Lifesciences® Granted Key International Patent in Australia for Its Proprietary Diabetes Neuromodulation Technology
ReShape Lifesciences® Signs Exclusive Distribution Agreement with Recon Supply to Access the VA and DoD Markets
ReShape Lifesciences® Announces Pricing of $2.6 Million Public Offering

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.